Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
15 September 2021Next earnings report:
26 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 36 min agoDividend
Analysts recommendations
Institutional Ownership
PRCT Latest News
SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time.
PROCEPT BioRobotics Corporation (PRCT) reported a quarterly loss of $0.51 per share, which was better than the expected loss of $0.55 per share according to Zacks Consensus Estimate. This is an improvement from the loss of $0.63 per share reported in the same quarter last year.
SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 1, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.
PROCEPT BioRobotics Corporation (PRCT) Q4 2023 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The mean of analysts' price targets for PROCEPT BioRobotics Corporation (PRCT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PROCEPT BioRobotics Corporation (PRCT) Q3 2023 Earnings Call Transcript
PRCT's aquablation therapy has shown strong growth, with revenues of $57.5mm in Q2 FY'23. The company's economic levers include new system placements, and growth from its installed base, with a record number of systems placed in Q2. Net-net, reiterate buy, eyeing a $40 price objective.
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.43 per share a year ago.
REDWOOD CITY, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2023 before market open on Thursday, July 27, 2023. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.
What type of business is PROCEPT BioRobotics?
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
What sector is PROCEPT BioRobotics in?
PROCEPT BioRobotics is in the Healthcare sector
What industry is PROCEPT BioRobotics in?
PROCEPT BioRobotics is in the Medical Devices industry
What country is PROCEPT BioRobotics from?
PROCEPT BioRobotics is headquartered in United States
When did PROCEPT BioRobotics go public?
PROCEPT BioRobotics initial public offering (IPO) was on 15 September 2021
What is PROCEPT BioRobotics website?
https://www.procept-biorobotics.com
Is PROCEPT BioRobotics in the S&P 500?
No, PROCEPT BioRobotics is not included in the S&P 500 index
Is PROCEPT BioRobotics in the NASDAQ 100?
No, PROCEPT BioRobotics is not included in the NASDAQ 100 index
Is PROCEPT BioRobotics in the Dow Jones?
No, PROCEPT BioRobotics is not included in the Dow Jones index
When does PROCEPT BioRobotics report earnings?
The next expected earnings date for PROCEPT BioRobotics is 26 July 2024